|
Vandetanib
|
凡德他尼
|
443913-73-3
|
|
Motesanib
|
莫特塞尼
|
453562-69-1
|
|
Nintedanib Ethanesulfonate Salt
|
尼达尼布乙磺酸盐
|
656247-18-6
|
|
Masitinib mesylate
|
马赛替尼
|
1048007-93-7
|
|
Dasatinib hydrochloride
|
达沙替尼盐酸盐
|
854001-07-3
|
|
Multi-kinase inhibitor 1
|
化合物MULTI-KINASE INHIBITOR I
|
778274-97-8
|
|
Mirk-IN-1
|
1386979-55-0
|
1386979-55-0
|
|
Orelabrutinib
|
奥布替尼
|
1655504-04-3
|
|
SU4312
|
SU 4312;NSC 86429;SU-4312;NSC-86429
|
5812-07-7
|
|
Pralsetinib
|
BLU-667（拉西替尼）
|
2097132-94-8
|
|
Acrizanib
|
化合物ACRIZANIB
|
1229453-99-9
|
|
Lanraplenib succinate
|
Lanraplenib (succinate)
|
1800047-00-0
|
|
UNC2025 hydrochloride
|
UNC2025 盐酸盐
|
2070015-17-5
|
|
ENMD-2076
|
6-(4-甲基-1-哌嗪基)-N-(5-甲基-1H-吡唑-3-基)-2-[(1E)-2-苯乙烯基]-4-嘧啶胺
|
934353-76-1
|
|
Ibrutinib-biotin
|
1599432-18-4
|
1599432-18-4
|
|
JH-VIII-157-02
|
化合物 T15612
|
1639422-97-1
|
|
SRI 31215 TFA
|
SRI-31215 BIS-TFA SALT
|
1832686-44-8
|
|
Tyrphostin AG1433
|
Tyrphostin AG1433
|
168835-90-3
|
|
Sunitinib Malate
|
苹果酸舒尼替尼
|
341031-54-7
|
|
Cabozantinib S-malate
|
苹果酸卡博替尼
|
1140909-48-3
|
|
Ningetinib Tosylate
|
对甲苯磺酸宁格替尼
|
1394820-77-9
|
|
BMS-935177
|
1231889-53-4
|
1231889-53-4
|
|
JNJ-38877618
|
JNJ-38877618
|
943540-74-7
|
|
TAS-115 mesylate
|
TAS-115 MESYLATE
|
1688673-09-7
|
|
AZ-Dyrk1B-33
|
3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine
|
1679330-37-0
|
|
Jaspamycin
|
JASPAMYCIN
|
22242-96-2
|
|
FGFR1/DDR2 inhibitor 1
|
FGFR1/DDR2 inhibitor 1
|
2308497-58-5
|
|
SU14813 maleate
|
5-[(Z)-(5-氟-1,2-二氢-2-氧代-3H-吲哚-3-亚基)甲基]-N-[(2S)-2-羟基-3-(4-吗啉基)丙基]-2,4-二甲基-1H-吡咯-3-甲酰胺马来酸盐
|
849643-15-8
|
|
Vorolanib
|
VOROLANIB
|
1013920-15-4
|
|
tBID
|
1639895-85-4
|
1639895-85-4
|
|
AZD7507
|
CS-2850
|
1041852-85-0
|
|
UNC2541
|
UNC2541
|
1612782-86-1
|
|
Y15
|
1,2,4,5-苯四胺四盐酸盐
|
4506-66-5
|
|
PF-573228
|
6-[(4-((3-(甲磺酰基)苄基)氨基)-5-三氟甲基嘧啶-2-基)氨基]-3,4-二氢-1H-喹啉-2-酮
|
869288-64-2
|
|
Pazopanib Hydrochloride
|
盐酸帕唑帕尼
|
635702-64-6
|
|
SU16f
|
化合物 T16947
|
251356-45-3
|
|
R406
|
6-[[5-氟-2-[(3,4,5-三甲氧基苯基)氨基]-4-嘧啶基]氨基]-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-恶嗪-3(4H)-酮苯磺酸盐
|
841290-81-1
|
|
Toceranib phosphate
|
托西尼布磷酸盐
|
874819-74-6
|
|
TG 100572 Hydrochloride
|
4-氯-3-[5-甲基-3-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-1,2,4-苯并三嗪-7-基]苯酚单盐酸盐
|
867331-64-4
|
|
Brigatinib
|
布格替尼
|
1197953-54-0
|
|
Btk inhibitor 2
|
Btk inhibitor 2
|
1558036-85-3
|
|
ARQ 531
|
ARQ-531
|
2095393-15-8
|
|
Rp-cAMPS sodium salt
|
ADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT
|
142439-94-9
|
|
Vecabrutinib
|
维卡布鲁替尼
|
1510829-06-7
|
|
Remibrutinib
|
LOU-064
|
1787294-07-8
|
|
BT-13
|
BT-13
|
924537-98-4
|
|
cFMS Receptor Inhibitor II
|
CFMS RECEPTOR INHIBITOR II
|
959860-85-6
|
|
Bozitinib
|
BOZITINIB (PLB-1001)
|
1440964-89-5
|
|
WRG-28
|
WRG-28
|
1913291-02-7
|
|
Lyn-IN-1
|
巴非替尼
|
887650-05-7
|
|
Lck inhibitor 2
|
3-[[4-[(5-羟基-2-甲基苯基)氨基]-2-嘧啶基]氨基]苯甲酰胺
|
944795-06-6
|
|
INDY
|
INDY
|
1169755-45-6
|
|
SKLB4771
|
FLT3-IN-1
|
1370256-78-2
|
|
Gilteritinib hemifumarate
|
GILTERITINIB FUMARATE
|
1254053-84-3
|
|
(±)-Zanubrutinib
|
(±)-赞鲁替尼
|
1633350-06-7
|
|
MAZ51
|
CS-2885
|
163655-37-6
|
|
RU-301
|
RU-301
|
1110873-99-8
|
|
PDGFRα kinase inhibitor 1
|
PDGFRα kinase inhibitor 1
|
2209053-93-8
|
|
SPP-86
|
1-(1-Methylethyl)-3-(2-phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
1357349-91-7
|
|
AG 1295
|
酪氨酸磷酸化抑制剂AG1295
|
71897-07-9
|
|
Nilotinib
|
尼罗替尼
|
641571-10-0
|
|
BMS-509744
|
N-(5-((5-(4-乙酰基哌嗪-1-甲酰基)-4-甲氧基-2-甲基苯基)硫基)噻唑-2-基)-4-(((3,3-二甲基丁烷-2-基)氨基)甲基)苯甲酰胺
|
439575-02-7
|
|
PF-06465469
|
PF 06465469
Discontinued See A191400
|
1407966-77-1
|
|
CHMFL-BMX-078
|
化合物CHMFL-BMX-078
|
1808288-51-8
|
|
TAK-659 hydrochloride
|
TAK-659 (HYDROCHLORIDE)
|
1952251-28-3
|
|
Ensartinib hydrochloride
|
2137030-98-7
|
2137030-98-7
|
|
PRN1008
|
瑞扎布鲁替尼
|
1575596-29-0
|
|
Bosutinib
|
伯舒替尼
|
380843-75-4
|
|
Rp-cAMPS triethylammonium salt
|
ADENOSINE 3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER, TRIETHYLAMMONIUM SALT
|
151837-09-1
|
|
A-770041
|
A-770041
|
869748-10-7
|
|
Lck Inhibitor
|
6-(2,6-二甲基苯基)-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-嘧啶并[5',4':5,6]嘧啶并[1,2-A]苯并咪唑-5(6H)-酮
|
847950-09-8
|
|
Tyrosine kinase inhibitor
|
DCL000409(XL184)
|
1021950-26-4
|
|
Ibrutinib D5
|
伊布替尼布D5
|
1553977-17-5
|
|
Tirbanibulin Mesylate
|
1080645-95-9
|
1080645-95-9
|
|
PRN694
|
1575818-46-0
|
1575818-46-0
|
|
TL02-59
|
3-(6,7-dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide
|
1315330-17-6
|
|
FN-1501
|
1429515-59-2
|
1429515-59-2
|
|
AZD3229 Tosylate
|
AZD3229 Tosylate
|
2248003-71-4
|
|
CLK-IN-T3
|
CLK inhibitor T3
(T3)
|
2109805-56-1
|
|
CSF1R-IN-1
|
CSF1R-IN-1
|
2095849-04-8
|
|
TAM-IN-2
|
TAM-IN-2
|
2135642-56-5
|
|
BPR1K871
|
1-(3-氯苯基)-3-(5-(2-((7-(3-(二甲基氨基)丙氧基)喹唑啉-4-基)氨基)乙基)噻唑-2-基)脲
|
2443767-35-7
|
|
AGL-2263
|
AG 2263
|
638213-98-6
|
|
Syk-IN-1
|
1,2,4-Triazine-6-carboxamide, 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-(1H-indol-7-ylamino)-
|
1491150-77-6
|
|
Tivozanib
|
替沃扎尼
|
475108-18-0
|
|
DPH
|
5-(3-(4-氟苯基)-1-苯基-1H-吡唑-4-基)咪唑烷-2,4-二酮
|
484049-04-9
|
|
Dovitinib lactate
|
多韦替尼乳酸盐
|
692737-80-7
|
|
KB SRC 4
|
1-[3-[1-([1,1'-Biphenyl]-3-ylMethyl)-1H-1,2,3-triazol-5-yl]phenyl]-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine
|
1380088-03-8
|
|
Osteogenic Growth Peptide (10-14)
|
OSTEOGENIC GROWTH PEPTIDE (10-14)
|
105250-85-9
|
|
trans-Pralsetinib
|
cis-Pralsetinib hydrochloride (cis-BLU-667 hydrochloride)
|
2097132-93-7
|
|
Hck-IN-1
|
Nef-IN-B9
|
1473404-51-1
|
|
Pivanex
|
(2,2-二甲基-1-氧代丙氧基)丁酸甲酯
|
122110-53-6
|
|
Petunidin chloride
|
矮牵牛素PT
|
1429-30-7
|
|
TIE-2/VEGFR-2 kinase-IN-1
|
6-(4-甲氧基苯基)呋喃并[2,3-D]嘧啶-4-胺
|
453590-24-4
|
|
PF-04217903 methanesulfonate
|
PF 04217903 MESYLATE
|
956906-93-7
|
|
Tirbanibulin dihydrochloride
|
5-[4-[2-(4-吗啉基)乙氧基]苯基]-N-(苯基甲基)-2-吡啶乙酰胺盐酸盐
|
1038395-65-1
|
|
3-Hydroxy Midostaurin
|
CGP52421
|
179237-49-1
|
|
Conteltinib
|
CONTELTINIB (CT-707)
|
1384860-29-0
|
|
PD173074
|
PD173074
|
219580-11-7
|
|
Sunitinib
|
舒尼替尼
|
557795-19-4
|